$1,318.00
This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Symptoms
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Targeted therapies
10 Chemotherapies
10 Steroids
11 Immunomodulators
11 Radiation therapy
11 CAR T-cell therapy
11 Stem cell transplantation
12 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Imbruvica for MCL (April 8, 2021)
26 Cirmtuzumab for MCL (December 7, 2020)
28 Parsaclisib for MCL (December 6, 2020)
29 Breyanzi for MCL (December 5, 2020)
31 Pirtobrutinib for MCL (December 5, 2020)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Lilly’s Non-Covalent BTK Inhibitor Pirtobrutinib
35 Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
35 Incyte Pulls Parsaclisib Files As FDA Takes Foot Off Accelerator
36 Incyte Bids For Broad Parsaclisib Lymphoma Label
36 Scottish Funding Wins for Kite’s CAR-T Tecartus & Five Other Products
37 PROBABILITY OF SUCCESS
38 REVENUE OPPORTUNITY
40 CLINICAL TRIAL LANDSCAPE
41 Sponsors by status
42 Sponsors by phase
44 BIBLIOGRAPHY
46 APPENDIX
LIST OF FIGURES
14 Figure 1: Global trends in incident cases of MCL, 2017–26
16 Figure 2: Global incident cases of MCL, by age, 2017
20 Figure 3: Overview of pipeline drugs for MCL in the US
20 Figure 4: Pipeline drugs for MCL, by company
21 Figure 5: Pipeline drugs for MCL, by drug type
21 Figure 6: Pipeline drugs for MCL, by classification
28 Figure 7: Cirmtuzumab for MCL (December 7, 2020): Phase Ib/II – CIRLL Study
31 Figure 8: Breyanzi for MCL (December 5, 2020): Phase I – TRANSCEND
33 Figure 9: Pirtobrutinib for MCL (December 5, 2020): Phase I/II – BRUIN
34 Figure 10: Key upcoming events in MCL
37 Figure 11: Probability of success in the MCL pipeline
40 Figure 12: Clinical trials in MCL
40 Figure 13: Top 10 drugs for clinical trials in MCL
41 Figure 14: Top 10 companies for clinical trials in MCL
41 Figure 15: Trial locations in MCL
42 Figure 16: MCL trials status
43 Figure 17: MCL trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of MCL, 2017–26
15 Table 2: Global incident cases of MCL, by gender, 2017
18 Table 3: Marketed drugs for MCL
22 Table 4: Pipeline drugs for MCL in the US
26 Table 5: Imbruvica for MCL (April 8, 2021)
27 Table 6: Cirmtuzumab for MCL (December 7, 2020)
29 Table 7: Parsaclisib for MCL (December 6, 2020)
30 Table 8: Breyanzi for MCL (December 5, 2020)
32 Table 9: Pirtobrutinib for MCL (December 5, 2020)
38 Table 10: Historical global sales, by drug ($m), 2017–21
39 Table 11: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!